CPX-351 improves survival in AML with myelodysplasia-related changes
New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
Case report describes myeloid sarcoma relapse in breast after nasal cavity presentation
A rare cancer returns to the breast six years after nasal treatment
This case report details the clinical course of a 68-year-old female with myeloid sarcoma and acute myeloid leukemia. The patient achieved c…
A rare blood cancer can hide in the breast for years and look exactly like a normal tumor without special lab tests
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes.
New AML Drug Shows Strong Response But Some Patients Face Higher Risk
This retrospective monocentric cohort study evaluated 60 consecutive patients treated with CPX-351 as first-line therapy for therapy-related…
A new leukemia drug helps most patients respond well, but those with high white blood cell counts or complex gene changes may face higher ri…
Meta-analysis identifies new genetic loci linked to acute myeloid leukemia risk in 4710 cases.
New Genetic Map Reveals Hidden Leukemia Risk Factors
This meta-analysis evaluated common genetic variants at 1q23.3, 2p23.3, 2q33.3, and 2p21 in 4710 AML cases and 12,938 controls. The authors …
New research pinpoints specific DNA changes that raise the odds of developing acute myeloid leukemia.
High prevalence and multidrug resistance of gram-negative bloodstream infections in children with acute myeloid leukemia
Antibiotic-Resistant Infections Are Hitting Kids With Leukemia Harder Than We Thought
This retrospective cohort study evaluated 90 children with acute myeloid leukemia admitted for induction chemotherapy at a single center. Th…
This research shows that drug-resistant infections are a major, often deadly threat to children undergoing leukemia treatment, highlighting …
Case report of ATRA and VAH regimen in refractory EVI1-positive AML
New hope for tough AML cases
This case report with a brief literature review describes a 42-year-old patient with refractory EVI1-positive AML. The patient achieved comp…
A patient with high-risk AML and the tough EVI1 marker achieved complete remission after failing standard treatments, offering new hope for …
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults
FDA approves new drug called Vanflyta for a specific type of blood cancer in adults.
Vanflyta is approved in combination with induction and consolidation chemotherapy, and as maintenance monotherapy, for adult patients with n…
FDA approves Vanflyta to treat acute myeloid leukemia in adults with a specific genetic change that makes the cancer harder to manage.
Narrative review explores immune monitoring for relapse prediction after AML stem cell transplant
Can better immune monitoring help predict relapse in leukemia patients after stem cell transplants?
This narrative review examines immune monitoring methodologies for predicting relapse in acute myeloid leukemia patients after allogeneic he…
New immune monitoring tools could spot leukemia relapse risks earlier than standard tests after stem cell transplants, helping doctors tailo…
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS. The analysis pooled …
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.